Protocol GS-US-256-0124: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy with GS-5885 in Combination with GS-9256 or GS-9451 or Tegobuvir with Peginterferon Alfa 2a and Ribavirin in Treatment Experienced S